Results 121 to 130 of about 480,468 (239)

In silico exploration of deep-sea fungal metabolites as inhibitor of Ebola and Marburg VP35 and VP40.

PLoS ONE
VP30 and VP40 proteins of Ebola and Marburg viruses have been recognized as potential targets for antiviral drug development due to their essential roles in the viral lifecycle.
Abdullah R Alanzi, Mohammed F Alajmi, Mohammed S Al-Dosari, Mohammad K Parvez, Moneerah J Alqahtani   +4 more
doaj   +1 more source

VP24-Karyopherin alpha binding affinities differ between Ebolavirus species, nfluencing interferon inhibition and VP24 stability [PDF]

, 2017
Zaire ebolavirus (EBOV), Bundibugyo ebolavirus (BDBV), and Reston ebolavirus (RESTV) belong to the same genus but exhibit different virulence properties.
Alinger, Joshua B, Amarasinghe, Gaya K, Basler, Christopher F, Diederichs, Audrey, Edwards, Megan R, Leung, Daisy W, Schwarz, Toni M   +6 more
core   +2 more sources

Silver Nanoparticle‐Mediated Antiviral Efficacy against Enveloped Viruses: A Comprehensive Review

Global Challenges, Volume 9, Issue 5, May 2025.
Silver nanoparticles (AgNPs) exhibit broad‐spectrum antiviral activity by targeting key viral structures and processes. They disrupt viral envelopes, compromising integrity, and bind to nucleocapsids, impairing viral replication. AgNPs also inhibit glycoprotein interactions, preventing viral attachment and entry into host cells.
Ekaterine Mosidze, Gianluigi Franci, Federica Dell'Annunziata, Nicoletta Capuano, Marica Colella, Flora Salzano, Massimiliano Galdiero, Aliosha Bakuridze, Veronica Folliero   +8 more
wiley   +1 more source

New Insights Into Marburg Virus Disease Pathogenesis in the Rhesus Macaque Model [PDF]

The Journal of Infectious Diseases, 2018
Previously, several studies have been performed to delineate the development and progression of Marburg virus infection in nonhuman primates (NHPs), primarily to clarify the mechanisms of severe (fatal) disease. After the 2013-2016 Ebola virus disease (EVD) epidemic in Western Africa, there has been a reassessment of the available filovirus animal ...
Kurt Cooper, Lisa E. Hensley, Timothy K. Cooper, David X. Liu, Peter B. Jahrling, Joshua C. Johnson, Jennifer Sword, John G. Bernbaum, Randy Hart, Amanda Bonilla   +9 more
openaire   +3 more sources

Filovirus receptor NPC1 contributes to species-specific patterns of ebolavirus susceptibility in bats [PDF]

, 2015
Biological factors that influence the host range and spillover of Ebola virus (EBOV) and other filoviruses remain enigmatic. While filoviruses infect diverse mammalian cell lines, we report that cells from African straw-colored fruit bats (Eidolon helvum)
Agnarsson, Allison, Almeida, Amman, Amman, Baker, Biesold, Bolger, Carette, Carroll, Carstea, Chandran, Cui, Côté, Daugherty, Deffieu, Delport, Demogines, Demogines, Drexler, Ebihara, Feldmann, Ge, Gire, Grabherr, He, Herbert, Hueffer, Jahrling, Jangra, Jayme, Jones, Kaelber, Kamins, Katzourakis, Krishnan, Kugelman, Kuhn, Kühl, Lee, Leroy, Li, Mali, Maruyama, Meyerson, Miller, Miller, Miller-Butterworth, Murrell, Negredo, Ng, Olival, Park, Parker, Paweska, Peel, Pond, Radoshitzky, Radoshitzky, Raj, Ren, Robertson, Ross, Runz, Ruxton, Sheahan, Swenson, Swenson, Takada, Taylor, Taylor, Taylor, Tong, Towner, Vanier, Volchkov, Wahl-Jensen, Wong, Yang   +78 more
core   +2 more sources

Anticipating the species jump: surveillance for emerging viral threats. [PDF]

, 2012
Zoonotic disease surveillance is typically triggered after animal pathogens have already infected humans. Are there ways to identify high-risk viruses before they emerge in humans? If so, then how and where can identifications be made and by what methods?
Bush, RM, Cobey, S, Flanagan, ML, Glass, GE, Leighton, TJ, Parrish, CR   +5 more
core   +1 more source

Exploring the role of identity, the other and negative attributions in conflict about biodiversity valuation

People and Nature, Volume 7, Issue 5, Page 1225-1239, May 2025.
Abstract Negotiating the many, often conflicting, values of biodiversity held by different stakeholders is a key endeavour in terms of integrating values into policy, co‐producing sustainable knowledge and achieving sustainable solutions. This negotiation is affected by stakeholders' agonistic identification processes, in which they express negative ...
Thomas Fickel, Adrian Rothers, Juliette C. Young   +2 more
wiley   +1 more source

Ebola virus VP30 and nucleoprotein interactions modulate viral RNA synthesis [PDF]

, 2017
Ebola virus (EBOV) is an enveloped negative-sense RNA virus that causes sporadic outbreaks with high case fatality rates. Ebola viral protein 30 (eVP30) plays a critical role in EBOV transcription initiation at the nucleoprotein (eNP) gene, with ...
Amarasinghe, Gaya K, Basler, Christopher F, Batra, Jyoti, Leung, Daisy W, Luthra, Priya, Wu, Chao, Xu, Wei   +6 more
core   +2 more sources

The macromolecular crystallography beamlines of the Helmholtz‐Zentrum Berlin at the BESSY II storage ring: history, current status and future directions

Journal of Synchrotron Radiation, Volume 32, Issue 3, Page 766-778, May 2025.
The history, current state and future directions of the three MX beamlines BL14.1, BL14.2 and BL14.3 of the Helmholtz‐Zentrum Berlin at the BESSY II electron storage ring are described.Since 2003, the Macromolecular Crystallography (MX) group at Helmholtz‐Zentrum Berlin (HZB) has been operating three MX beamlines at the BESSY II storage ring in Berlin.
Uwe Mueller, Tatjana Barthel, Laila S. Benz, Volodymyr Bon, Thomas Crosskey, Camilla Genter Dieguez, Ronald Förster, Christine Gless, Thomas Hauß, Udo Heinemann, Michael Hellmig, David James, Frank Lennartz, Melanie Oelker, Ruslan Ovsyannikov, Parinita Singh, Markus C. Wahl, Gert Weber, Manfred S. Weiss   +18 more
wiley   +1 more source

Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization. [PDF]

, 2017
BACKGROUND: The recent West African Ebola epidemic led to accelerated efforts to test Ebola vaccine candidates. As part of the World Health Organisation-led VSV Ebola Consortium (VEBCON), we performed a phase I clinical trial investigating rVSV-ZEBOV (a ...
Addo, MM, Becker, S, Biedenkopf, N, Borregaard, S, Dahlke, C, Eickmann, M, Fehling, SK, Jambrecina, A, Kasonta, R, Krähling, V, Lohse, AW, Lunemann, S, Ly, ML, Lütgehetmann, M, Olearo, F, Rechtien, A, Schmiedel, S, Spohn, M, Stahl, F, Strecker, T, Stubbe, HC, VEBCON Consortium, Zinser, ME   +22 more
core   +1 more source